SC Orders Panel to Stop Unethical Pharma Marketing
In a landmark step aimed at shielding healthcare consumers from manipulative commercial practices, the Supreme Court of India on Thursday directed the Central Government to constitute a dedicated expert committee to eliminate unethical marketing practices across the pharmaceutical industry. A division bench comprising Justice Vikram Nath and Justice Sandeep Mehta issued the order while adjudicating a public interest plea demanding enforceable guidelines to curb unregulated promotional inducements, doctor gifts, and misleading drug branding until a formal statutory law takes effect nationwide. The bench underlined that commercial interests must not compromise public health, setting January 29 as the next hearing date to review the Centre's compliance affidavit.
Three-Member Panel to Draft Legal Framework: UCPMP 2024 to Serve as Interim Guardrail
Addressing the top court, the Union Government confirmed the establishment of a specialized three-member committee tasked with assessing industry inputs and framing comprehensive recommendations for a robust legal structure. The Centre submitted that extensive internal consultations highlighted the necessity of strengthening existing oversight systems to prevent pharmaceutical conglomerates from exploiting marketing loopholes. While the panel requested an initial two-month window to compile its findings and submit an actionable blueprint, the government assured the court that the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 will remain actively enforceable across the manufacturing, distribution, and clinical ecosystem until the final statutory framework is implemented.
January 29 Review: Transitioning from Voluntary Codes to Statutory Enforcement
The ongoing judicial scrutiny comes amid persistent concerns raised by health advocacy networks over the limitations of voluntary industry codes in preventing covert kickbacks, luxury travel sponsorships, and excessive incentives provided to medical practitioners for prescribing specific branded medications. By mandating an official committee and locking in a judicial compliance deadline for January 29, the Supreme Court has set in motion the legal groundwork required to make pharmaceutical promotional ethics legally binding. The forthcoming framework is anticipated to impose heavy punitive liabilities on defaulting pharmaceutical corporations, ensuring pricing transparency, evidence-based prescriptions, and consumer trust across the Indian healthcare market.
